The PHG Foundation's report calls for raising clinician awareness about ctDNA testing technology in order to improve patient access to targeted therapies.
The bill, which was approved by a Senate subcommittee yesterday, would increase the National Institutes of Health's fiscal 2018 budget to $36.1 billion.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
The Bidens have convened a diverse board and staff with the goal of continuing efforts to accelerate research and development begun under the Cancer Moonshot Initiative.
Entering a new chapter with a new leader, ACLA lends support to a draft bill that would regulate lab tests not as medical devices but as in vitro clinical tests.
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.
The draft bill, based on a proposal developed by a coalition of Dx manufacturers and labs, would split oversight responsibilities across the FDA, CMS, and states.
Enrolling more participants from groups underrepresented in biomedical research is a laudable goal, but the current administration's policies may make it hard to achieve.
In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.
